SCHEMBL47623

SCHEMBL47623

CN(Cc1ccccn1)C(=O)[C@@H]1CCCC[C@@H]1C(=O)C(C)(C)C

nearest known ligand 0.44

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ TSHR P16473 1/20 0.43
▸ KMT2A Q03164 2/20 0.42
▸ KDM4E B2RXH2 1/20 0.41
▸ ALDH1A1 P00352 1/20 0.41
▸ HPGD P15428 2/20 0.40
▸ MEN1 O00255 1/20 0.40
▸ MMP2 P08253 1/20 0.40
▸ BMP1 P13497 1/20 0.40
▸ RECQL P46063 1/20 0.39
▸ AGTR2 P50052 2/20 0.39
▸ RAB9A P51151 1/20 0.39
▸ HSD11B1 P28845 1/20 0.39
▸ PLAT P00750 1/20 0.39
▸ CYP1A2 P05177 1/20 0.39
▸ CYP3A4 P08684 1/20 0.38
▸ LMNA P02545 2/20 0.38
▸ SMN1; SMN2 Q16637 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL47662 1.00 TSHR (0.43) TSHRKMT2AKDM4EALDH1A1HPGD
SCHEMBL16521997 0.77 HPGD (0.55) TSHRKMT2AKDM4EALDH1A1HPGD
SCHEMBL26478903 0.77 HPGD (0.55) TSHRKMT2AKDM4EALDH1A1HPGD
SCHEMBL16521992 0.77 HPGD (0.55) TSHRKMT2AKDM4EALDH1A1HPGD
SCHEMBL12265795 0.75 POLB (0.51) TSHRKMT2AKDM4EALDH1A1AGTR2
SCHEMBL12900870 0.73 TSHR (0.45) TSHRKMT2AALDH1A1HPGDMEN1
SCHEMBL14707987 0.73 TSHR (0.45) TSHRKMT2AALDH1A1HPGDMEN1
SCHEMBL9887648 0.73 TSHR (0.45) TSHRKMT2AALDH1A1HPGDMEN1
SCHEMBL427048 0.70 SMN1; SMN2 (0.52) TSHRKMT2AKDM4EALDH1A1RAB9A
SCHEMBL6204342 0.70 KDM4E (0.52) TSHRKMT2AKDM4EALDH1A1CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180185452-A1 Dry Growth Hormone Composition Transiently Linked to a Polymer Carrier ASCENDIS PHARMA ENDOCRINOLOGY DIVISION A/S (DK) 2018-07-05 — — US disclosed
US-9919033-B2 Dry growth hormone composition transiently linked to a polymer carrier ASCENDIS PHARMA ENDOCRINOLOGY DIVISION A/S (DK) 2018-03-20 — — US disclosed
US-20170112939-A1 PREVENTION AND TREATMENT OF OCULAR CONDITIONS Ascendis Pharma Ophthamology Division A/S (DK) 2017-04-27 — — US disclosed
US-20170100490-A1 Prodrug Comprising a Drug Linker Conjugate ASCENDIS PHARMA A/S (DK) 2017-04-13 — — US disclosed
US-20170056477-A1 Dry Growth Hormone Composition Transiently Linked to a Polymer Carrier ASCENDIS PHARMA GROWTH DISORDERS DIVISION A/S (DK) 2017-03-02 — — US disclosed
US-9511122-B2 Dry growth hormone composition transiently linked to a polymer carrier ASCENDIS PHARMA GROWTH DISORDERS DIVISION A/S (DK) 2016-12-06 — — US disclosed
US-20160206702-A1 PEGylated Recombinant Human Growth Hormone Compounds ASCENDIS PHARMA GROWTH DISORDERS DIVISION A/S (DK) 2016-07-21 — — US disclosed
US-9272048-B2 PEGylated recombinant human growth hormone compounds ASCENDIS PHARMA GROWTH DISORDERS DIVISION A/S (DK) 2016-03-01 — — US disclosed
US-20150290337-A1 DIAGNOSIS, PREVENTION AND TREATMENT OF DISEASES OF THE JOINT ASCENDIS PHARMA INC. 2015-10-15 — — US disclosed
US-20150010634-A1 PREVENTION AND TREATMENT OF OCULAR CONDITIONS Ascendis Pharma Ophthamology Division A/S (DK) 2015-01-08 — — US disclosed
US-8906847-B2 Prodrug comprising a drug linker conjugate ASCENDIS PHARMA A/S (DK) 2014-12-09 — — US disclosed
US-20140323402-A1 Protein Carrier-Linked Prodrugs Ascendis Phama A/S (DK) 2014-10-30 — — US disclosed
US-20140296257-A1 High-Loading Water-Soluable Carrier-Linked Prodrugs ASCENDIS PHARMA A/S (DK) 2014-10-02 — — US disclosed
US-20140243254-A1 Polymeric Hyperbranched Carrier-Linked Prodrugs ASCENDIS PHARMA A/S (DK) 2014-08-28 — — US disclosed
US-20120322721-A1 DRY GROWTH HORMONE COMPOSITION TRANSIENTLY LINKED TO A POLYMER CARRIER ASCENDIS PHARMA ENDOCRINOLOGY DIVISION A/S (DK) 2012-12-20 — — US disclosed
US-20120156259-A1 Biodegradable Polyethylene Glycol Based Water-Insoluble Hydrogels ASCENDIS PHARMA A/S (DK) 2012-06-21 — — US disclosed
US-20120058084-A1 Interferon Alpha Carrier Prodrugs ASCENDIS PHARMA AS (DK) 2012-03-08 — — US disclosed
US-20110112021-A1 PEGYLATED RECOMBINANT HUMAN GROWTH HORMONE COMPOUNDS ASCENDIS PHARMA AS (DK) 2011-05-12 — — US disclosed
US-20110053848-A1 PRODRUG COMPRISING A DRUG LINKER CONJUGATE ASCENDIS PHARMA AS (DK) 2011-03-03 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (15 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140296257-A1 High-Loading Water-Soluable Carrier-Linked Prodrugs ABCB11, SLCO1B1, SLC7A1 TSHR 4063/4885KMT2A 2949/4885KDM4E 3887/4885
US-20170112939-A1 PREVENTION AND TREATMENT OF OCULAR CONDITIONS PDE6C, ALDH1A2, UACA TSHR 2660/4885KMT2A 4600/4885KDM4E 4186/4885
US-20120322721-A1 DRY GROWTH HORMONE COMPOSITION TRANSIENTLY LINKED TO A POLYMER CARRIER GHRHR, GHSR, GCG TSHR 132/4885KMT2A 1703/4885KDM4E 2150/4885
US-20120156259-A1 Biodegradable Polyethylene Glycol Based Water-Insoluble Hydrogels PLG, PHYKPL, PLOD3 TSHR 3360/4885KMT2A 3136/4885KDM4E 1756/4885
US-20150290337-A1 DIAGNOSIS, PREVENTION AND TREATMENT OF DISEASES OF THE JOINT ADAMTS13, ADAMTS5, TNF TSHR 3966/4885KMT2A 3995/4885KDM4E 4331/4885
US-20170056477-A1 Dry Growth Hormone Composition Transiently Linked to a Polymer Carrier GHRHR, GHSR, GCG TSHR 132/4885KMT2A 1703/4885KDM4E 2150/4885
US-20170100490-A1 Prodrug Comprising a Drug Linker Conjugate H1-0, H1-3, H1-2 TSHR 991/4885KMT2A 327/4885KDM4E 1446/4885
US-20110112021-A1 PEGYLATED RECOMBINANT HUMAN GROWTH HORMONE COMPOUNDS GHRHR, GHITM, GHSR TSHR 29/4885KMT2A 2937/4885KDM4E 3989/4885
US-20160206702-A1 PEGylated Recombinant Human Growth Hormone Compounds GHRHR, GHITM, GHSR TSHR 29/4885KMT2A 2937/4885KDM4E 3989/4885
US-20140243254-A1 Polymeric Hyperbranched Carrier-Linked Prodrugs P4HA1, CYP8B1, PAH TSHR 3949/4885KMT2A 2583/4885KDM4E 3467/4885
US-20110053848-A1 PRODRUG COMPRISING A DRUG LINKER CONJUGATE H1-0, H1-3, H1-2 TSHR 997/4885KMT2A 327/4885KDM4E 1429/4885
US-20140323402-A1 Protein Carrier-Linked Prodrugs SLC6A7, PRAP1, PELP1 TSHR 3425/4885KMT2A 4580/4885KDM4E 4594/4885
US-20180185452-A1 Dry Growth Hormone Composition Transiently Linked to a Polymer Carrier GHRHR, GHSR, GCG TSHR 132/4885KMT2A 1703/4885KDM4E 2150/4885
US-20150010634-A1 PREVENTION AND TREATMENT OF OCULAR CONDITIONS PDE6C, ALDH1A2, UACA TSHR 2660/4885KMT2A 4600/4885KDM4E 4186/4885
US-20120058084-A1 Interferon Alpha Carrier Prodrugs IFNG, IFNAR1, IRF3 TSHR 3312/4885KMT2A 4563/4885KDM4E 4661/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback